| Screening | Evaluation |
---|
 |  |
Baseline
|
6Â months
|
12Â months
|
18Â months
|
24Â months
|
Eligibility criteria | x | Â | Â | Â | Â | Â |
Informed consent | x | Â | Â | Â | Â | Â |
Health care use | Â | Â | x | X | x | x |
MCSI | Â | x | x | x | x | x |
CGI | Â | x | x | x | x | x |
MINI | Â | x | x | x | x | x |
MARS | Â | x | x | x | x | x |
SF-36 | Â | x | x | x | x | x |
S-QoL 18 | Â | x | x | x | x | x |
EuroQoL 5D | Â | x | x | x | x | x |
RAS | Â | x | x | x | x | x |
MCAS | x | x | x | x | x | x |
Ad hoc questionnaires | Â | x | x | x | x | x |
Cost analysis | Â | Â | x | x | x | x |
-
CGI, clinical global impression; Health care use, number of admissions to hospital, total days in hospital and number of emergency department visits; MARS, medication adherence rating scale (MARS); MCAS, Multnomah community integration scale MINI, mini international neuropsychiatric interview, sections K and L; MCSI, modified Colorado symptom index; RAS, recovery assessment scale; SF-36, medical outcomes study 36-item short form health survey; S-QoL 18, schizophrenia quality of life questionnaire.